NasdaqCM:BYSI

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology cancer therapies.


Snowflake Analysis

Adequate balance sheet with weak fundamentals.

Share Price & News

How has BeyondSpring's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: BYSI's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-5.7%

BYSI

-0.9%

US Biotechs

2.5%

US Market


1 Year Return

6.1%

BYSI

24.5%

US Biotechs

8.4%

US Market

Return vs Industry: BYSI underperformed the US Biotechs industry which returned 23.8% over the past year.

Return vs Market: BYSI exceeded the US Market which returned 4.6% over the past year.


Shareholder returns

BYSIIndustryMarket
7 Day-5.7%-0.9%2.5%
30 Day26.7%3.2%5.1%
90 Day3.8%13.6%2.0%
1 Year6.1%6.1%25.7%24.5%10.9%8.4%
3 Year-51.8%-51.8%32.2%27.8%30.5%21.9%
5 Yearn/a-3.4%-9.2%56.9%39.2%

Price Volatility Vs. Market

How volatile is BeyondSpring's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is BeyondSpring undervalued compared to its fair value and its price relative to the market?

15.48x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate BYSI's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate BYSI's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: BYSI is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: BYSI is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate BYSI's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: BYSI is overvalued based on its PB Ratio (15.5x) compared to the US Biotechs industry average (3.8x).


Next Steps

Future Growth

How is BeyondSpring forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

55.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: BYSI is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: BYSI is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: BYSI is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if BYSI's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if BYSI's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if BYSI's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has BeyondSpring performed over the past 5 years?

-25.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: BYSI is currently unprofitable.

Growing Profit Margin: BYSI is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: BYSI is unprofitable, and losses have increased over the past 5 years at a rate of -25.6% per year.

Accelerating Growth: Unable to compare BYSI's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BYSI is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.5%).


Return on Equity

High ROE: BYSI has a negative Return on Equity (-129.56%), as it is currently unprofitable.


Next Steps

Financial Health

How is BeyondSpring's financial position?


Financial Position Analysis

Short Term Liabilities: BYSI's short term assets ($40.9M) exceed its short term liabilities ($10.1M).

Long Term Liabilities: BYSI's short term assets ($40.9M) exceed its long term liabilities ($3.4M).


Debt to Equity History and Analysis

Debt Level: BYSI's debt to equity ratio (4.7%) is considered satisfactory.

Reducing Debt: BYSI had negative shareholder equity 5 years ago, but is now positive and has therefore improved.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: BYSI has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: BYSI has less than a year of cash runway if free cash flow continues to reduce at historical rates of 40.1% each year


Next Steps

Dividend

What is BeyondSpring's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate BYSI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate BYSI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BYSI's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BYSI's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of BYSI's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.1yrs

Average management tenure


CEO

Lan Huang (48yo)

5.5yrs

Tenure

Dr. Lan Huang, Ph.D., co-founded BeyondSpring Pharmaceuticals, Inc. in 2013 and serves as its Chairman and Chief Executive Officer. Dr. Huang Co-founded BeyondSpring Inc. and has been its Chairman and Chi ...


Leadership Team

NamePositionTenureCompensationOwnership
Lan Huang
Co-Founder5.5yrsno data37.18% $174.3m
Dongheng Liu
Chief Financial Officer2.17yrsno data0.56% $2.6m
Richard Daly
Chief Operating Officer1.75yrsno datano data
James Tonra
Chief Scientific Officer2.08yrsno datano data
Stephen Kilmer
Head of Investor Relationsno datano datano data
Gregg Russo
Senior Vice President of Human Resources0.50yrno datano data
Ramon Mohanlal
Executive VP of Research & Development0.33yrno data0.79% $3.7m
G. Lloyd
Chief Scientific Officer Emeritus & Senior Advisorno datano data0.072% $336.2k
Gordon Schooley
Chief Regulatory Officerno datano data0.00049% $2.3k
Amy Yang
Controllerno datano datano data

2.1yrs

Average Tenure

58yo

Average Age

Experienced Management: BYSI's management team is considered experienced (2.1 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Lan Huang
Co-Founder5.5yrsno data37.18% $174.3m
Ramon Mohanlal
Executive VP of Research & Development0.33yrno data0.79% $3.7m
Matthew Kirkby
Independent Director3.58yrsno data0.017% $80.1k
Patrick Fabbio
Independent Director2.33yrsno data0.014% $65.9k
Douglas Blayney
Member of Scientific Advisors & Principal Investigators Boardno datano datano data
Quanqi Song
Independent Director4yrsno data2.47% $11.6m
Yanbin Xie
Independent Director4yrsno data0.015% $71.0k
Christine Zhao
Independent Director3.58yrsno data0.017% $80.1k
Jeffrey Crawford
Member of Scientific Advisors & Principal Investigators Boardno datano datano data
Yuankai Shi
Member of Scientific Advisors & Principal Investigators Boardno datano datano data

3.6yrs

Average Tenure

52.5yo

Average Age

Experienced Board: BYSI's board of directors are considered experienced (3.6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 20.3%.


Top Shareholders

Company Information

BeyondSpring Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: BeyondSpring Inc.
  • Ticker: BYSI
  • Exchange: NasdaqCM
  • Founded: 2010
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$468.757m
  • Shares outstanding: 27.89m
  • Website: https://www.beyondspringpharma.com

Number of Employees


Location

  • BeyondSpring Inc.
  • 28 Liberty Street
  • 39th Floor
  • New York
  • New York
  • 10005
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BYSINasdaqCM (Nasdaq Capital Market)YesOrdinary SharesUSUSDMar 2017

Biography

BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology cancer therapies. The company’s lead asset is the Plinabulin that is in late stage clinical trials as an anti-cancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC) for the prevention of high and intermediate risk chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab for the treatment of NSCLC; and programmed cell death protein 1 and CTLA-4 antibodies to treat small cell lung cancer. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform using ubiquitin mediated protein degradation pathway. BeyondSpring Inc. has collaboration agreements with the University of Washington and the Fred Hutchinson Cancer Research Center. The company was founded in 2010 and is headquartered in New York, New York. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/05/27 09:14
End of Day Share Price2020/05/26 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.